SequelSEC

Quince Therapeutics, Inc. QNCX

Biological Products, (No Diagnostic Substances) · CIK 0001662774 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$127.16M
Fiscal year ended 2026-06-30
Free cash flow
-$47.00M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$64.00MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.39Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio0.53x14th

Quince Therapeutics, Inc. (QNCX) reported net income of -$92.48M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Quince Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Quince Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
RevenueUnavailable
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$127.16M
Net income-$92.48M
Research & development$32.99M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expense-$2.16M
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$27.81M
Selling & marketingUnavailable

Balance

Quince Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$115.98M
Total assets$124.00M
Current assets$123.41M
Total liabilities$15.51M
Current liabilities$8.50M
Total equity incl. NCI-$35.32M
Temporary (mezzanine) equity$143.81M
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$4.64M

Cash flow

Quince Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$46.92M
Capital expenditures$78.00K
Investing cash flow$26.29M
Financing cash flow$121.79M
Net change in cash$99.16M
Stock-based compensation$15.82M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$152.00K

Derived

Quince Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$47.00M
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio14.52x
Revenue YoY growthUnavailable
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open QNCX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-04-10View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.